Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Integral Diagnostics (ASX:IDX) share price up on acquisition

The Integral Diagnostics (ASX:IDX) share price is rising higher after it announced an acquisition called The X-Ray Group.

The Integral Diagnostics Ltd (ASX: IDX) share price is rising higher after it announced an acquisition.

Integral Diagnostics is a provider of medical imaging services. It has over 60 clinics across multiple brands in Australia and New Zealand.

Integral Diagnostics acquires The X-Ray Group

Today the company announced that it is acquiring The X-Ray Group for an upfront value of $37.5 million made up by a combination of cash and shares. A further $1 million will be paid in three years.

Integral Diagnostics said that $25.95 million will make up the cash portion of the payment. The shares portion of the transaction is $11.55 million worth of Integral Diagnostics shares to be issued when the acquisition is completed.

It will fund the transaction with existing debt facilities.

As part of the deal, there is a possibility of an extra $4 million for FY22 and $2.5 million for FY23 to the sellers if The X-Ray Group meets EBITDA performance targets.

Integral Diagnostics said that the deal is subject to “customary conditions” and is expected to be completed in November 2021.

The X-Ray Group and its synergies for Integral Diagnostics

Integral Diagnostics said that The X-Ray Group is complementary to its existing regional footprint. It has potential operational synergies and growth opportunities.

The X-Ray Group is a group of radiology clinics in Albury and Wodonga, along the Victorian and New South Wales border. It also has three smaller community clinics in Wangaratta, Yarrawonga and Lavington.

It has a projected FY22 EBITDA of between $5 million and $5.5 million, before any COVID impacts. Unfortunately, it didn’t specify any details on what the COVID impacts might be.

Final thoughts on the Integral Diagnostics share price

The Integral Diagnostics share price has done well through COVID. It initially dropped sharply in March 2020 but recovered quickly and was back to pre-COVID levels in August 2020.

In reaction to the acquisition the Integral Diagnostics share price is up 3.8% at the time of writing.

I’m not sure if it is a buy at this share price as it is not a company I have put the research into. For investors who are considering if Integral Diagnostics is a buy, I recommend our FREE share valuation course for both newer investors and more experienced investors who want a refresher.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content